glp 1 and weight watchers WeightWatchers bankruptcy: 5 alternatives for loss drugs GLP-1 Medications for Weight Loss:

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial

[No authors listed] GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes

De Block CEM, Dirinck E, Verhaegen A, Van Gaal LF

Figure 2 Importantly, in the SELECT trial, differences in rates of cardiovascular events between semaglutide and placebo began to emerge within the first few months suggesting that weight loss alone may not account for the full benefits ( On the co-morbidities front, GLP-1R is not expressed in the liver and the data generated with semaglutide in NASH patients seems to support a lack of a direct antifibrotic effect (152)

[DOI] [PubMed] [Google Scholar] Nauck M.A., Meier J.J